中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (7): 538-544.doi: 10.19401/j.cnki.1007-3639.2018.07.011

• 综述 • 上一篇    下一篇

乳腺癌新辅助内分泌治疗的研究进展

金恺睿 综述,俞晓立 审校   

  1. 复旦大学附属肿瘤医院放疗科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2018-07-30 发布日期:2018-08-10
  • 通信作者: 俞晓立 E-mail: stephanieyxl@hotmail.com
  • 基金资助:
    国家自然科学基金青年项目(81402525);上海市卫生和计划生育委员会科研课题计划资助(201440425)。

Research progress of neoadjuvant hormonal therapy for breast cancer

JIN Kairui, YU Xiaoli   

  1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2018-07-30 Online:2018-08-10
  • Contact: YU Xiaoli E-mail: stephanieyxl@hotmail.com

摘要: 新辅助内分泌治疗作为新辅助化疗的一种安全有效的替代和补充,正被越来越多地应用于激素受体阳性的局部晚期乳腺癌患者中。但新辅助内分泌治疗在适应患者的筛选、疗效、预后的评判及治疗规范等方面仍存在诸多争议。现从新辅助内分泌治疗与新辅助化疗的比较、不同新辅助内分泌药物的比较、新辅助内分泌治疗的疗程、新辅助内分泌治疗联合化疗或靶向药物、新辅助内分泌治疗疗效、预后的评判及新辅助内分泌治疗后的辅助放疗指征等方面总结新辅助内分泌治疗的现状和进展。

关键词: 乳腺癌, 新辅助内分泌治疗, 进展

Abstract: As a safe and effective substitute and supplement of neoadjuvant chemotherapy (NCT), neoadjuvant hormonal therapy (NHT) has been increasingly used in patients with locally advanced breast cancer whose hormone receptors are positive. However, there are many controversies of NHT in the standard treatment, indications and assessment of the treatment effects. To review the current situation and research progress of NHT, this article discusses the following aspects: comparison of NCT and NHT, comparison of different NHT treatments, duration of NHT, combination of NHT and other neoadjuvant treatments, predictors of response and prognosis, and adjuvant radiation indications after NHT.

Key words: Breast cancer, Neoadjuvant hormonal therapy, Progress